CE-Ventures leads the $26 million Series A funding round for Exeliom Biosciences

CE-Ventures leads the $26 million Series A funding round for Exeliom Biosciences

CE-Ventures, the corporate venture capital platform of Crescent Enterprises, a leading global, diversified business headquartered in the UAE, announced that it successfully led the extension to the Series A funding round totalling US$26 million in Exeliom Biosciences, a France-based, clinical-stage biopharmaceutical company specialised in the development of microbiome-based immunotherapies. Exeliom Biosciences is on a mission to bring innovation to the pharmaceutical treatment of inflammatory bowel diseases, cancer, and infectious diseases. The microbiome consists of all living organisms - including microbes, bacteria, protozoa, and fungi, that reside in and on the human body, mostly in the gastrointestinal tract and on the skin. The human microbiome market is projected to reach US$3.1 billion by 2029 from US$600 million in 2021, at a CAGR of 23%. On leading the Series A round, Tushar Singhvi, Deputy CEO and Head of Investments, Crescent Enterprises said: “CE-Ventures is excited and bullish about the transformative potential that innovative fields, such as microbiome hold. It represents a frontier of scientific discovery and therapeutic potential, which we firmly believe has the power to reshape healthcare as we know it. Our investment in this sector is guided by the conviction that understanding and leveraging the microbiome could unlock significant improvements